摘要
目的探讨慢性乙型肝炎（CHB）患者，血清丙氨酸氨基转移酶（ALT）水平对指导拉米夫定治疗的意义。方法按治疗前血清ALT水平将105例CHB患者分为三组：其中，ALT〉200IU组32例，ALT100～200IU组38例，ALT〈100IU组35例。所有受试对象在接受拉米夫定治疗一年后，采用荧光定量PCR法检测血清HBVDNA含量，采用ELISA法检测血清乙肝两对半。结果治疗后，ALT〉200IU组和ALT100～200IU组的患者血清HBVDNA含量明显低于ALT％100IU组的患者（分别P〈0．01和P〈0．05）；ALT〉200IU组的患者血清HBVDNA阴转率、HBeAg阴转率和HBeAb转换率明显高于ALT〈100IU组的患者（P〈0．05）。结论治疗前ALT水平高的CHB患者对拉米夫定可能更为敏感。
Objective To explore the relationship between serum alanine aminotransferase （ALT） level in patients with chronic hepatitis B （CHB） and the therapeutic effect of lamivudine. Methods According to serum ALT level before the therapy, 105 patients with CHB were divided into three groups： ALT〉200 IU group with 32 cases, ALT 100-200 IU group with 38 cases, ALT〈100 IU group with 35 cases. Above three groups were treated by lamivudine for one year. Serum HBV DNA level and HBV markers in three groups were measured by quantitative PCR of fluorimetry and and ELISA respectively. Results After the therapy, serum HBV DNA level in ALT〉200 IU group and ALT 100-200 IU group were significantly lower than that in ALT〈100 IU group （P〈 0.01 and P〈 0.05, respectively）, while serum HBV DNA negative rate as well as HBeAg negative rate and HBeAb positive rate in ALT〉200 IU group were significantly higher than that in ALT〈100 IU group （P〈 0.05）. Conclusion The patients with CHB who have high serum ALT level before the therapy may be more sensitive to lamivudine.
出处
《福建医药杂志》
CAS
2008年第4期97-98,共2页
Fujian Medical Journal
关键词
慢性乙型肝炎
丙氨酸氨基转氨酶
拉米夫定
疗效
Chronic hepatitis B
Alanine aminotransferase
Lamivudine
Therapeutic effect
